Since 2014, the US FDA has approved six PD-1/PD-L1 inhibitors for cancer treatment, all of them being monoclonal antibody drugs, including pembrolizumab, nivolumab, duvalumab, atezolizumab, avelumab, and cemiplimab. The gene discussed is PDCD1; the disease is cancer.